Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
AK129
/
Akesobio
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|||||
|||||
AK129
/
Akesobio
,
Kaitanni
(cadonilimab) /
Akesobio
New P1/2 trial, Metastases:
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma
(clinicaltrials.gov) - Sep 19, 2024
P1/2
, N=294, Not yet recruiting,
Sponsor: Akeso
|||
|||||||
AK129
/
Akesobio
Enrollment open, Metastases:
A Study of AK129 in Patients With Advanced Malignant Tumors
(clinicaltrials.gov) - Sep 21, 2023
P1a/1b
, N=182, Recruiting,
Sponsor: Akeso
Not yet recruiting --> Recruiting
|||
|||||||
AK129
/
Akesobio
New P1 trial, Metastases:
A Study of AK129 in Patients With Advanced Malignant Tumors
(clinicaltrials.gov) - Dec 9, 2022
P1a/1b
, N=181, Not yet recruiting,
Sponsor: Akeso